Inflammation-induced reduction of spontaneous activity by adjuvant: A novel model to study the effect of analgesics in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 1, 2007, Pages 194-201

  Matson, David J ^a   Broom, Daniel C ^a   Carson, Susan R ^a   Baldassari, James ^a   Kehne, John ^a   Cortright, Daniel N ^b  

^a Department of Pharmacology ^*  (United States)

^b NEUROGEN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMPHETAMINE; CELECOXIB; DEXAMETHASONE; FREUND ADJUVANT; GABAPENTIN; IBUPROFEN; MORPHINE; PIROXICAM; ROFECOXIB;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; EXPERIMENTAL MODEL; INFLAMMATION; KNEE PAIN; MALE; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ANALGESIA; ANALGESICS; ANIMALS; CARRAGEENAN; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FREUND'S ADJUVANT; INFLAMMATION; KAOLIN; MALE; MODELS, ANIMAL; MORPHINE; MOTOR ACTIVITY; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES;

EID: 33845871512     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.109736     Document Type: Article

References (29)

1. Broom DC, Samad TA, Kohno T, Tegeder I, Geisslinger G, and Woolf CJ (2004) Cyclooxygenase 2 expression in the spared nerve injury model of neuropathic pain. Neuroscience 124:891-900.
2. Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, et al. (1999) Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor: pharmacological and biochemical profiles. J Pharmacol Exp Ther 290:551-560.
3. Chaplan SR, Bach FW, Pogrel JW, Chung JM, and Yaksh TL (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53:55-63.
4. Coulthard P, Pleuvry BJ, Brewster M, Wilson KL, and Macfarlane TV (2002) Gait analysis as an objective measure in a chronic pain model. J Neurosci Methods 116:197-213.
5. Coulthard P, Simjee SU, and Pleuvry BJ (2003) Gait analysis as a correlate of pain induced by carrageenan intraplantar injection. J Neurosci Methods 128:95-102.
6. Fernihough J, Gentry C, Malcangio M, Fox A, Rediske J, Pellas T, Kidd B, Bevan S, and Winter J (2004) Pain related behaviour in two models of osteoarthritis in the rat knee. Pain 112:83-93.
7. Field MJ, Gonzalez MI, Tallarida RJ, and Singh L (2002) Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. J Pharmacol Exp Ther 303:730-735.
8. Francischi JN, Chaves CT, Moura AC, Lima AS, Rocha OA, Ferreira-Alves DL, and Bakhle YS (2002) Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. Br J Pharmacol 137:837-844.
9. Gegout P, Gillet P, Terlain B, and Netter P (1995) Zymosan-induced arthritis in rats: II. Effects of anti-inflammatory drugs. Life Sci 56:PL389-394.
10. Gilron I, Orr E, Tu D, O'Neill JP, Zamora JE, and Bell AC (2005) A placebo-controlled randomized clinical trial of perioperative administration of gabapentin, rofecoxib and their combination for spontaneous and movement-evoked pain after abdominal hysterectomy. Pain 113:191-200.
11. Hargreaves K, Dubner R, Brown F, Flores C, and Joris J (1988) A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32:77-88.
12. Harris RR, Black L, Surapaneni S, Kolasa T, Majest S, Namovic MT, Grayson G, Komater V, Wilcox D, King L, et al. (2004) ABT-963 [2-(3,4-difluoro-phenyl)- 4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfony [SCAP]L-phenyl)-2H- pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxygenase-2 inhibitor. J Pharmacol Exp Ther 311:904-912.
13. Jones CK, Peters SC, and Shannon HE (2005) Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther 312:726-732.
14. Lu Y and Westlund KN (1999) Gabapentin attenuates nociceptive behaviors in an acute arthritis model in rats. J Pharmacol Exp Ther 290:214-219.
15. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, and Seibert K (1994) Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91:3228-3232.
16. Mazurski EJ and Beninger RJ (1988) Stimulant effects of apomorphine and ()-amphetamine in rats with varied habituation to test environment. Pharmacol Biochem Behav 29:249-255.
17. Millecamps M, Etienne M, Jourdan D, Eschalier A, and Ardid D (2004) Decrease in non-selective, non-sustained attention induced by a chronic visceral inflammatory state as a new pain evaluation in rats. Pain 109:214-224.
18. Nagakura Y, Okada M, Kohara A, Kiso T, Toya T, Iwai A, Wanibuchi F, and Yamaguchi T (2003) Allodynia and hyperalgesia in adjuvant-induced arthritic rats: time course of progression and efficacy of analgesics. J Pharmacol Exp Ther 306:490-497.
19. Pomonis JD, Boulet JM, Gottshall SL, Phillips S, Sellers R, Bunton T, and Walker K (2005) Development and pharmacological characterization of a rat model of osteoarthritis pain. Pain 114:339-346.
20. Randal L and Selitto J (1957) A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn 111:409-419.
21. Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, et al. (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296:558-566.
22. Safieh-Garabedian B, Poole S, Allchorne A, Winter J, and Woolf CJ (1995) Contribution of interleukin-1 beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br J Pharmacol 115:1265-1275.
23. Simjee SU, Pleuvry BJ, and Coulthard P (2004) Modulation of the gait deficit in arthritic rats by infusions of muscimol and bicuculline. Pain 109:453-460.
24. Sluka KA and Westlund KN (1993) Behavioral and immunohistochemical changes in an experimental arthritis model in rats. Pain 55:367-377.
25. Vierck CJ, Acosta-Rua AJ, and Johnson RD (2005) Bilateral chronic constriction of the sciatic nerve: a model of long-term cold hyperalgesia. J Pain 6:507-517.
26. Vrinten DH and Hamers FF (2003) "CatWalk" automated quantitative gait analysis as a novel method to assess mechanical allodynia in the rat; a comparison with von Frey testing. Pain 102:203-209.
27. Whiteside GT, Harrison J, Boulet J, Mark L, Pearson M, Gottshall S, and Walker K (2004) Pharmacological characterisation of a rat model of incisional pain. Br J Pharmacol 141:85-91.
28. Yu YC, Koo ST, Kim CH, Lyu Y, Grady JJ, and Chung JM (2002) Two variables that can be used as pain indices in experimental animal models of arthritis. J Neurosci Methods 115:107-113.
29. Zimmermann M (1983) Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16:109-110.